Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments.

Perrin SL, Samuel MS, Koszyca B, Brown MP, Ebert LM, Oksdath M, Gomez GA.

Biochem Soc Trans. 2019 Apr 30;47(2):625-638. doi: 10.1042/BST20180444. Epub 2019 Mar 22. Review.

PMID:
30902924
2.

Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma.

Bougnaud S, Golebiewska A, Oudin A, Keunen O, Harter PN, Mäder L, Azuaje F, Fritah S, Stieber D, Kaoma T, Vallar L, Brons NH, Daubon T, Miletic H, Sundstrøm T, Herold-Mende C, Mittelbronn M, Bjerkvig R, Niclou SP.

Oncotarget. 2016 May 31;7(22):31955-71. doi: 10.18632/oncotarget.7454.

3.

The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour.

Smith SJ, Diksin M, Chhaya S, Sairam S, Estevez-Cebrero MA, Rahman R.

Int J Mol Sci. 2017 Nov 18;18(11). pii: E2452. doi: 10.3390/ijms18112452.

4.

Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.

Xia S, Lal B, Tung B, Wang S, Goodwin CR, Laterra J.

Neuro Oncol. 2016 Apr;18(4):507-17. doi: 10.1093/neuonc/nov171. Epub 2015 Aug 27.

5.

Role of extracellular matrix and microenvironment in regulation of tumor growth and LAR-mediated invasion in glioblastoma.

Kim Y, Kang H, Powathil G, Kim H, Trucu D, Lee W, Lawler S, Chaplain M.

PLoS One. 2018 Oct 4;13(10):e0204865. doi: 10.1371/journal.pone.0204865. eCollection 2018.

6.

Adaptive Changes of Glioblastoma Cells Following Exposure to Hypoxic (1% Oxygen) Tumour Microenvironment.

Musah-Eroje A, Watson S.

Int J Mol Sci. 2019 Apr 28;20(9). pii: E2091. doi: 10.3390/ijms20092091.

7.

Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.

Poon CC, Sarkar S, Yong VW, Kelly JJP.

Brain. 2017 Jun 1;140(6):1548-1560. doi: 10.1093/brain/aww355. Review.

PMID:
28334886
8.

Immune Microenvironment in Glioblastoma Subtypes.

Chen Z, Hambardzumyan D.

Front Immunol. 2018 May 8;9:1004. doi: 10.3389/fimmu.2018.01004. eCollection 2018. Review.

9.

A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo.

Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, Prager BC, Couce M, McLendon RE, Sloan AE, Rich JN.

Cancer Res. 2016 Apr 15;76(8):2465-77. doi: 10.1158/0008-5472.CAN-15-2402. Epub 2016 Feb 19.

10.

3D extracellular matrix interactions modulate tumour cell growth, invasion and angiogenesis in engineered tumour microenvironments.

Taubenberger AV, Bray LJ, Haller B, Shaposhnykov A, Binner M, Freudenberg U, Guck J, Werner C.

Acta Biomater. 2016 May;36:73-85. doi: 10.1016/j.actbio.2016.03.017. Epub 2016 Mar 10.

PMID:
26971667
11.

The emergent role of exosomes in glioma.

Gourlay J, Morokoff AP, Luwor RB, Zhu HJ, Kaye AH, Stylli SS.

J Clin Neurosci. 2017 Jan;35:13-23. doi: 10.1016/j.jocn.2016.09.021. Epub 2016 Oct 19. Review.

PMID:
27771233
12.

The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells.

Huang J, Chen K, Chen J, Gong W, Dunlop NM, Howard OM, Gao Y, Bian XW, Wang JM.

Br J Cancer. 2010 Mar 16;102(6):1052-60. doi: 10.1038/sj.bjc.6605591. Epub 2010 Mar 2.

13.

Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies.

Denysenko T, Gennero L, Roos MA, Melcarne A, Juenemann C, Faccani G, Morra I, Cavallo G, Reguzzi S, Pescarmona G, Ponzetto A.

Cell Biochem Funct. 2010 Jul;28(5):343-51. doi: 10.1002/cbf.1666. Review.

PMID:
20535838
14.

Combination therapy to checkmate Glioblastoma: clinical challenges and advances.

Ghosh D, Nandi S, Bhattacharjee S.

Clin Transl Med. 2018 Oct 16;7(1):33. doi: 10.1186/s40169-018-0211-8. Review.

15.

Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis.

Cui X, Morales RT, Qian W, Wang H, Gagner JP, Dolgalev I, Placantonakis D, Zagzag D, Cimmino L, Snuderl M, Lam RHW, Chen W.

Biomaterials. 2018 Apr;161:164-178. doi: 10.1016/j.biomaterials.2018.01.053. Epub 2018 Feb 3.

PMID:
29421553
16.

Tumour progression and metastasis.

Arvelo F, Sojo F, Cotte C.

Ecancermedicalscience. 2016 Jan 29;10:617. doi: 10.3332/ecancer.2016.617. eCollection 2016. Review.

17.

Therapeutic targets in malignant glioblastoma microenvironment.

Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A.

Semin Radiat Oncol. 2009 Jul;19(3):163-70. doi: 10.1016/j.semradonc.2009.02.004. Review.

18.

Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma.

Simon T, Pinioti S, Schellenberger P, Rajeeve V, Wendler F, Cutillas PR, King A, Stebbing J, Giamas G.

Mol Cancer. 2018 Aug 31;17(1):132. doi: 10.1186/s12943-018-0878-x.

19.

Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.

Marques-Torrejon MA, Gangoso E, Pollard SM.

Dis Model Mech. 2018 Feb 22;11(2). pii: dmm031435. doi: 10.1242/dmm.031435.

20.

Microenvironment driven invasion: a multiscale multimodel investigation.

Anderson AR, Rejniak KA, Gerlee P, Quaranta V.

J Math Biol. 2009 Apr;58(4-5):579-624. doi: 10.1007/s00285-008-0210-2. Epub 2008 Oct 7.

Supplemental Content

Support Center